Extent of asleep blood pressure reduction by hypertension medications is ingestion-time dependent: Systematic review and meta-analysis of published human trials
- PMID: 33571840
- DOI: 10.1016/j.smrv.2021.101454
Extent of asleep blood pressure reduction by hypertension medications is ingestion-time dependent: Systematic review and meta-analysis of published human trials
Abstract
Combined evidence of published prospective outcome trials and meta-analyses substantiate elevated asleep blood pressure (BP) and blunted sleep-time relative BP decline (non-dipping), regardless of wake-time office BP and awake or 24 h BP means, are jointly the most highly significant independent prognostic markers of cardiovascular disease (CVD) risk and worthy therapeutic targets for prevention. Nonetheless, current guidelines continue to recommend the diagnosis of hypertension, when based on ambulatory BP monitoring (ABPM), rely, solely, on either the 24 h or "daytime" BP means. They also fail to recommend the time to treat patients. We conducted a systematic review of published human trials regarding ingestion-time differences in the effects of hypertension medications on asleep BP and sleep-time relative BP decline. Some 62 such trials published between 1992 and 2020, totaling 6120 hypertensive persons, evaluated 21 different single and 8 dual-fixed combination therapies. The vast (82.3%) majority of the trials substantiate the bedtime/evening vs. upon-waking/morning treatment schedule produces statistically significant better clinical benefits, including enhanced reduction of asleep systolic BP by an average 5.17 mmHg (95%CI [4.04, 6.31], P < 0.001 between treatment-time groups) without inducing sleep-time hypotension, reduced prevalence of the high CVD risk non-dipper 24 h BP pattern, improved kidney function, and reduced cardiac pathology. Furthermore, systematic and comprehensive review of the ABPM-based literature published the past 29 years reveals no single study that reported significantly better benefits of the most recommended, yet unjustified by medical evidence, morning hypertension treatment-time scheme.
Keywords: Asleep blood pressure; Bedtime hypertension chronotherapy; Blood pressure dipping; Chronopharmacology; Hypertension medications; Pharmacodynamics; Sleep-time relative blood pressure decline.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflicts of interest Ramón C. Hermida, Michael H. Smolensky, Artemio Mojón, and José R. Fernández have shares of Circadian Ambulatory Technology & Diagnostics (CAT&D), a technology-based company developed by and in partnership with the University of Vigo.
Comment in
-
Is the bedtime ingestion of hypertensive medications effective and safe?Sleep Med Rev. 2021 Oct;59:101511. doi: 10.1016/j.smrv.2021.101511. Epub 2021 Jun 5. Sleep Med Rev. 2021. PMID: 34175781 No abstract available.
Similar articles
-
Elevated asleep blood pressure and non-dipper 24h patterning best predict risk for heart failure that can be averted by bedtime hypertension chronotherapy: A review of the published literature.Chronobiol Int. 2023 Jan;40(1):63-82. doi: 10.1080/07420528.2021.1939367. Epub 2021 Jun 30. Chronobiol Int. 2023. PMID: 34190016 Review.
-
Systematic review and quality evaluation of published human ingestion-time trials of blood pressure-lowering medications and their combinations.Chronobiol Int. 2021 Oct;38(10):1460-1476. doi: 10.1080/07420528.2021.1931280. Epub 2021 Jun 9. Chronobiol Int. 2021. PMID: 34107831
-
Guidelines for the design and conduct of human clinical trials on ingestion-time differences - chronopharmacology and chronotherapy - of hypertension medications.Chronobiol Int. 2021 Jan;38(1):1-26. doi: 10.1080/07420528.2020.1850468. Epub 2020 Dec 20. Chronobiol Int. 2021. PMID: 33342316 Free PMC article. Clinical Trial.
-
Ingestion-time differences in the pharmacodynamics of dual-combination hypertension therapies: Systematic review and meta-analysis of published human trials.Chronobiol Int. 2022 Apr;39(4):493-512. doi: 10.1080/07420528.2021.2005084. Epub 2021 Dec 14. Chronobiol Int. 2022. PMID: 34906002
-
Ingestion-time differences in the pharmacodynamics of hypertension medications: Systematic review of human chronopharmacology trials.Adv Drug Deliv Rev. 2021 Mar;170:200-213. doi: 10.1016/j.addr.2021.01.013. Epub 2021 Jan 22. Adv Drug Deliv Rev. 2021. PMID: 33486007
Cited by
-
Dosing time optimization of antihypertensive medications by including the circadian rhythm in pharmacokinetic-pharmacodynamic models.PLoS Comput Biol. 2022 Nov 14;18(11):e1010711. doi: 10.1371/journal.pcbi.1010711. eCollection 2022 Nov. PLoS Comput Biol. 2022. PMID: 36374862 Free PMC article.
-
Timing of Novel Drug 1A-116 to Circadian Rhythms Improves Therapeutic Effects against Glioblastoma.Pharmaceutics. 2021 Jul 16;13(7):1091. doi: 10.3390/pharmaceutics13071091. Pharmaceutics. 2021. PMID: 34371781 Free PMC article.
-
Clocks, Rhythms, Sex, and Hearts: How Disrupted Circadian Rhythms, Time-of-Day, and Sex Influence Cardiovascular Health.Biomolecules. 2021 Jun 14;11(6):883. doi: 10.3390/biom11060883. Biomolecules. 2021. PMID: 34198706 Free PMC article. Review.
-
One Health: Circadian Medicine Benefits Both Non-human Animals and Humans Alike.J Biol Rhythms. 2024 Jun;39(3):237-269. doi: 10.1177/07487304241228021. Epub 2024 Feb 20. J Biol Rhythms. 2024. PMID: 38379166 Free PMC article. Review.
-
Chronotherapy for Hypertension: A Meta-Analysis and Systematic Review of RCTs.Am J Cardiovasc Drugs. 2025 Sep;25(5):633-654. doi: 10.1007/s40256-025-00731-2. Epub 2025 Apr 19. Am J Cardiovasc Drugs. 2025. PMID: 40251431
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous